QuVa Pharma FDA-483

FDA has released the form FDA-483 issued following a 7/11-8/18/22 inspection at QuVa Pharma, a Sugar Land, TX, outsourcing facility. The three inspection observations were:

  • employees engaged in the manufacture and processing of a drug product lack the training required to perform their assigned functions;
  • determination of conformance to appropriate written specifications for acceptance of drug products is deficient; and
  • the written stability testing program is not followed.

Read more